May 6 | 2021
2cureX publishes the annual report for the fiscal year 2020
Read more
May 5 | 2021
Sista dag för handel med teckningsoptionerna av serie TO1 i 2cureX AB är idag, den 5 maj 2021
Read more
April 27 | 2021
2cureX’s CEO Fernando Andreu is buying shares in the company
Read more
April 26 | 2021
Board and management of 2cureX exercise all held warrants of series TO1 for SEK 6.04 million
Read more
April 26 | 2021
2cureX styrelse och ledning nyttjar samtliga innehavda teckningsoptioner av serie TO1 för 6,04 MSEK
Read more
April 24 | 2021
Correction of “Notice to attend the Annual General Meeting of 2cureX AB” issued on 23[rd] April 2021.
Read more
April 24 | 2021
Korrektion till ”Kallelse till årsstämma i 2cureX AB” utfärdad den 23 april 2021.
Read more
April 23 | 2021
Notice to attend the Annual General Meeting of 2cureX AB
Read more
April 23 | 2021
Kallelse till årsstämma i 2cureX AB
Read more
April 23 | 2021
Teckningskursen för utnyttjande av teckningsoptioner av serie TO1 i 2cureX AB har fastställts till 13,22 SEK och teckningsperioden inleds den 26 april 2021
Read more
April 23 | 2021
The exercise price for the warrants of series TO1 in 2cureX AB has been determined to SEK 13.22 and the subscription period starts April 26, 2021
Read more
March 2 | 2021
2cureX Clinical Newsletter
Read more
March 1 | 2021
2cureX announces that the clinical trial of IndiTreat®-guided treatment of metastatic colorectal cancer has met the primary endpoint.
Read more
February 25 | 2021
2cureX offentliggör bokslutskommuniké för räkenskapsåret 2020.
Read more
February 25 | 2021
2cureX publishes year-end report for 2020.
Read more
February 4 | 2021
IndiTreat® selected to prestigious multinational ovarian cancer project.
Read more
January 28 | 2021
2cureX appoints Kenneth Graabek Johansen, an experienced business and financial executive, as new CFO.
Read more
January 21 | 2021
Last patient treated in the world’s first interventional trial with 3D microtumors as guide for choice of cancer treatment.
Read more